Running the Biopharma Marathon
When I moved to Boston over thirty years ago, I had never even heard of the…
Rare Diseases: Shaping Biopharma’s Future from the Past
We just completed Rare Disease month. With that in mind, Sue has asked me to…
“Rare Disease” Is More Than Just a Day
You might think it odd for me to begin this month’s e-conversation with a quote…
Patient Advocacy – Delivering on Patient Centricity in Drug Development
Historically, biopharma companies developed drugs for patients with an illness…
Spotlight on Transitions
This topic of “transition” came home to me (literally and figuratively) over the Thanksgiving holiday. With our adult kids returning, my husband and…
Optimizing Your Essential Commercialization Teams
For those of you following closely (thank you!), you may recall that in an earlier e-conversation — 21st Century Commercialization — More than a…
Where Are Decisions Made in Your Organization (And Why Does It Matter)?
At your next company lunch and learn, try this experiment: Ask ten people from different functions to take a blank piece of flip chart paper…
Reading Recommendations from the High Cs
Summer is a wonderful time for catching up on our reading – whether business, pleasure, or something in between. This month, we sought out…
Are Your Assumptions Serving You Well?
Ah, June, the season of life transitions — weddings, graduations, school progression and, with the year nearly half over, a reminder to reflect on…
The Future of Biopharma Commercialization Is Now
Back in the early 2000s, I was head of commercial strategy at Millennium Pharmaceuticals in Cambridge, Massachusetts. I remember saying to then CEO,…